Aerie Pharmaceuticals' GAAP loss for Q2 2021 was $38.688 million, down 19.7% from $48.187 million in the prior year. Revenue increased 50.8% to $27.185 million from $18.033 million a year earlier.
Aerie Pharmaceuticals' GAAP loss for Q2 2021 was $38.688 million, down 19.7% from $48.187 million in the prior year. Revenue increased 50.8% to $27.185 million from $18.033 million a year earlier. 
investors.aeriepharma.com
English (US) 